Approved in 1996, Copaxone ® is the global market leader in the treatment of relapsing-remitting multiple sclerosis (RRMS) Ongoing, prospective, clinical trial follow-up reinforces the established ...
Sales of Teva’s multiple sclerosis blockbuster Copaxone are likely to peak this year before gradually giving way as more therapeutic options become available, a Teva exec says. The head of global ...
Shares of Teva Pharmaceutical Industries LimitedTEVA were down around 4% on Tuesday, as another generic version of its blockbuster multiple sclerosis injection, Copaxone was launched earlier than ...
Additional Preclinical Data to be Presented at the Fifth Joint Triennial Congress of ECTRIMS and ACTRIMS Further Elucidate the Anti-inflammatory Mechanism of COPAXONE® JERUSALEM--(BUSINESS WIRE)-- ...
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that a three-member panel of the European Patent Office’s (EPO) Opposition Division upheld patent ...
Teva Pharmaceutical (TEVA 2.93%) has its hands full. Its peers are challenging patents protecting its best-selling drug, Copaxone, and that puts billions of dollars at risk. However, Teva ...
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced up to 7-year efficacy, safety and tolerability results from the Glatiramer Acetate Low-Frequency Administration (GALA) ...
Copaxone is a prescription drug used to treat different types of multiple sclerosis (MS) in adults. It can cause side effects that range from mild to serious, including injection site reactions, ...
KANSAS CITY, Mo. (November 15, 2005) -- Clinical research data published in the December issue of Multiple Sclerosis provided evidence that COPAXONE® (glatiramer acetate injection) may offer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback